SANTA CRUZ BIOTECHNOLOGY, INC.

# CTAGE3 (N-13): sc-84074

SANTA CRUZ BIOTECHNOLOGY

*The Power to Question*

## BACKGROUND

Cutaneous T cell lymphomas (CTCL) represent a group of malignancies that originate from CD4-T lymphocytes and manifest on the skin. CTCL is a general term for several neoplasms including mycosis fungoides, T cell leukemia/lymphoma and pagetoid reticulosis, all of which are very difficult to treat in the advanced stages. CTAGE3 (cutaneous T cell lymphoma associated-antigen 3) is a member of the cancer/testis antigen family of proteins and is expressed in normal tissues including colon, mammary gland, ovary, placenta, stomach and testis, as well as several fetal tissues. CTAGE3 is a 158 amino acid protein that has been detected in mycosis fungoides tissues and T-zone lymphomas. This evidence suggests a potential role for CTAGE3 in the immunotherapy of cutaneous T-cell lymphomas and other malignancies.

## REFERENCES


1. Eichmuller, S., et al. 2001. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc. Natl. Acad. Sci. USA 98: 629-634.
2. Eichmüller, S. 2002. Towards defining specific antigens for cutaneous lymphomas. Onkologie 25: 448-454.
3. Eichmüller, S., et al. 2003. Tumor-specific antigens in cutaneous T-cell lymphoma: expression and sero-reactivity. Int. J. Cancer 104: 482-487.
4. Usener, D., et al. 2003. cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. J. Invest. Dermatol. 121: 198-206.
5. Atanackovic, D., et al. 2006. Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol. Ther. 5: 1218-1225.
6. Costa, F.F., et al. 2007. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 25: 707-711.
7. SWISS-PROT/TrEMBL (Q8IX95). World Wide Web URL: http://www.uniprot.org/uniprot/Q8IX95


## CHROMOSOMAL LOCATION

Genetic locus: CTAGE3P (human) mapping to 13p13.

## SOURCE

CTAGE3 (N-13) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping near the N-terminus of CTAGE3 of human origin.

## PRODUCT

Each vial contains 100 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-84074 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

## STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## APPLICATIONS

CTAGE3 (N-13) is recommended for detection of CTAGE3 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Molecular Weight of CTAGE3: 18 kDa.

## RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

## DATA



CTAGE3 (N-13): sc-84074. Immunofluorescence staining of formalin-fixed HepG2 cells showing cytoplasmic and membrane localization.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.